Sales of diabetes drugs should keep growing at about 10 percent a year for the rest of the decade, reaching $65 billion a year by 2020, says Jeffrey Holford, an analyst with Jefferies & Co. At that pace, diabetes drug revenues should more than double from the current $30 billion by the decade’s end. Holford says diabetes drug revenues should rise in relation to the aging population in the West, while in emerging markets, diabetes and obesity are increasing and access to health care is also growing. Other factors considered include higher drug prices, strong patent protection for key drugs, ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.